
    
      The study will be an 18-month, prospective, multi-center, double-blind, dose finding study
      with subjects who have undergone definitive treatment (surgery, cryotherapy, radiation
      therapy or brachytherapy) for primary prostate tumor and have had documented rising PSA on a
      minimum of 3 time points each at least 1 month apart, higher than the reference value noted
      within 1 year of study entry.
    
  